目的：评估超声睫状体成形术(UCP)+抗VEGF+全视网膜光凝手术(PRP)治疗晚期新生血管性青光眼的安全性及有效性。

方法：回顾性研究。收集2020-08/2022-09就诊于我院的晚期新生血管性青光眼患者45例45眼，根据治疗方案分为UCP+抗VEGF+PRP组16例16眼、经巩膜睫状体光凝(TCP)+抗VEGF+PRP组20例20眼、单纯UCP组9例9眼。比较三组患者术前，术后1 d，1 wk，1、3 mo眼压、疼痛评分、术后用药、有效率、总成功率及并发症发生情况。

结果：三组患者术前眼压、疼痛评分、术前用药比较均无差异(均P>0.05)，术后1 d，1 wk，1、3 mo眼压、疼痛评分较术前比较均有差异(均P<0.01)。术后1 mo单纯UCP组眼压(31.78±10.23 mmHg)高于UCP+抗VEGF+PRP组(19.44±8.23 mmHg)及TCP+抗VEGF+PRP组(20.80±10.27 mmHg)(均P<0.017)。术后1 d，1 wk TCP+抗VEGF+PRP组疼痛评分高于UCP+抗VEGF+PRP组及单纯UCP组(均P<0.017)。术后3 mo UCP+抗VEGF+PRP组、TCP+抗VEGF+PRP组、单纯UCP组(有效率分别为81%(13/16)、75%(15/20)、67%(6/9)(P=0.675)； 成功率分别为69%(11/16)、50%(10/20)、0(0/9)(P=0.003)。三组患者术后并发症比较均无差异(P>0.05)。

结论：UCP+抗VEGF+PRP与TCP+抗VEGF+PRP治疗晚期新生血管性青光眼患者降眼压效果相当。UCP+抗VEGF+PRP术后患者疼痛更轻，且无严重并发症。单纯UCP手术可在术后早期有效控制眼压，减轻患者疼痛，但长期控制仍需联合抗VEGF+PRP。

METHODS: Retrospective study. A total of 45 patients(45 eyes)with advanced NVG who received surgery in our hospital from August 2020 to September 2022 were collected and divided into UCP+ anti-VEGF +PRP group(16 patients, 16 eyes), transscleral cyclophotocoagulation(TCP)+anti-VEGF+PRP group(20 patients, 20 eyes), UCP alone group(9 patients, 9 eyes). The intraocular pressure, pain scores, postoperative medication, effective rate, total success rate and the incidence of complications of the patients in the three groups were compared before surgery and at 1 d, 1 wk, 1 and 3 mo after surgery.

RESULTS: There was no significant difference in preoperative intraocular pressure, pain scores and preoperative medication of patients in the three groups(all P>0.05). While there were statistical significance in the intraocular pressure and pain scores at 1 d, 1 wk, 1 and 3 mo after surgery(all P<0.01). The intraocular pressure of the UCP alone group(31.78±10.23 mmHg)was found to be higher than that of both the UCP+ anti-VEGF +PRP group(19.44±8.23 mmHg)and the TCP+ anti-VEGF +PRP group(20.80±10.27 mmHg)at 1 mo postoperatively(all P<0.017). The pain score of the TCP+ anti-VEGF +PRP group at 1 d and 1 wk postoperatively was higher than both the UCP+ anti-VEGF +PRP group and the UCP alone group(all P<0.017). The effective rates of UCP+ anti-VEGF +PRP group, TCP+ anti-VEGF +PRP group and UCP alone group were 81%(13/16), 75%(15/20)and 67%(6/9), respectively,(P=0.675), and the success rates were 69%(11/16), 50%(10/20), and 0(0/9), respectively(P=0.003). There was no significant difference in complications of patients in the three groups(P>0.05).

CONCLUSION: UCP combined with anti-VEGF +PRP and TCP combined with anti-VEGF +PRP showed comparable efficacy in reducing intraocular pressure in advanced NVG. UCP combined with anti-VEGF+PRP was more effective in relieving pain and with no serious complications in advanced NVG. UCP alone can effectively control intraocular pressure and alleviate the pain of patients in the early postoperative period, but long-term control still requires anti-VEGF+PRP.